Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 5/20 | 0.74 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.74 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.54 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.54 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.54 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.54 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.54 |
| ▸ | P2RY10 | O00398 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4551608 | 1.00 | ITGB3 (0.74) | ITGB3ITGA2BTP53TSHRLMNA | |
| SCHEMBL7142923 | 0.99 | ITGB3 (0.77) | ITGB3ITGA2BTP53TSHRLMNA | |
| SCHEMBL31193421 | 0.99 | ITGB3 (0.77) | ITGB3ITGA2BTP53TSHRLMNA | |
| SCHEMBL1960615 | 0.99 | ITGB3 (0.77) | ITGB3ITGA2BTP53TSHRLMNA | |
| SCHEMBL1960616 | 0.99 | ITGB3 (0.77) | ITGB3ITGA2BTP53TSHRLMNA | |
| SCHEMBL7142926 | 0.99 | ITGB3 (0.77) | ITGB3ITGA2BTP53TSHRLMNA | |
| SCHEMBL157969 | 0.97 | ITGB3 (0.74) | ITGB3ITGA2BLMNA | |
| SCHEMBL8530276 | 0.97 | ITGB3 (0.74) | ITGB3ITGA2BLMNA | |
| SCHEMBL157968 | 0.97 | ITGB3 (0.74) | ITGB3ITGA2BLMNA | |
| Hydrochloric Acid SCHEMBL16816253 | 0.95 | ITGB3 (0.72) | ITGB3ITGA2BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2036918-A1 | PEPTIDE DERIVATIVE | Vexon, Inc. (JP) | 2009-03-18 | — | — | EP | claimed |
| US-20080009448-A1 | Peptide Derivative | VEXON, INC. (50%) (JP) | 2008-01-10 | — | — | US | claimed |
| EP-2036918-A1 | PEPTIDE DERIVATIVE | Vexon, Inc. (JP) | 2009-03-18 | — | — | EP | disclosed |
| US-20080009448-A1 | Peptide Derivative | VEXON, INC. (50%) (JP) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009448-A1 | Peptide Derivative | ARGLU1, NGLY1, NPR3 | ITGB3 2199/4885ITGA2B 3637/4885TP53 3839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.